JP6641265B2 - ポリマーフィルム - Google Patents
ポリマーフィルム Download PDFInfo
- Publication number
- JP6641265B2 JP6641265B2 JP2016515393A JP2016515393A JP6641265B2 JP 6641265 B2 JP6641265 B2 JP 6641265B2 JP 2016515393 A JP2016515393 A JP 2016515393A JP 2016515393 A JP2016515393 A JP 2016515393A JP 6641265 B2 JP6641265 B2 JP 6641265B2
- Authority
- JP
- Japan
- Prior art keywords
- polymer film
- crosslinker
- monomer
- functional group
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920006254 polymer film Polymers 0.000 title claims description 71
- 239000004971 Cross linker Substances 0.000 claims description 60
- 239000000178 monomer Substances 0.000 claims description 60
- 239000003431 cross linking reagent Substances 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 29
- 125000000524 functional group Chemical group 0.000 claims description 28
- 239000011159 matrix material Substances 0.000 claims description 22
- 239000003999 initiator Substances 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 14
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 150000007970 thio esters Chemical class 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 102000005600 Cathepsins Human genes 0.000 claims description 7
- 108010084457 Cathepsins Proteins 0.000 claims description 7
- 102000029816 Collagenase Human genes 0.000 claims description 7
- 108060005980 Collagenase Proteins 0.000 claims description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 7
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 7
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 7
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 7
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical group CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 229960002424 collagenase Drugs 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 5
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 5
- 230000007515 enzymatic degradation Effects 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000243 solution Substances 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 24
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- 238000006116 polymerization reaction Methods 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- -1 glycidylamino Chemical group 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229940048053 acrylate Drugs 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- 230000007073 chemical hydrolysis Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010526 radical polymerization reaction Methods 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- HABAXTXIECRCKH-UHFFFAOYSA-N bis(prop-2-enyl) butanedioate Chemical compound C=CCOC(=O)CCC(=O)OCC=C HABAXTXIECRCKH-UHFFFAOYSA-N 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 2
- KYCQOKLOSUBEJK-UHFFFAOYSA-M 1-butyl-3-methylimidazol-3-ium;bromide Chemical compound [Br-].CCCCN1C=C[N+](C)=C1 KYCQOKLOSUBEJK-UHFFFAOYSA-M 0.000 description 2
- HCZMHWVFVZAHCR-UHFFFAOYSA-N 2-[2-(2-sulfanylethoxy)ethoxy]ethanethiol Chemical compound SCCOCCOCCS HCZMHWVFVZAHCR-UHFFFAOYSA-N 0.000 description 2
- QLIBJPGWWSHWBF-UHFFFAOYSA-N 2-aminoethyl methacrylate Chemical compound CC(=C)C(=O)OCCN QLIBJPGWWSHWBF-UHFFFAOYSA-N 0.000 description 2
- GWZMWHWAWHPNHN-UHFFFAOYSA-N 2-hydroxypropyl prop-2-enoate Chemical compound CC(O)COC(=O)C=C GWZMWHWAWHPNHN-UHFFFAOYSA-N 0.000 description 2
- SNCMCDMEYCLVBO-UHFFFAOYSA-N 3-aminopropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCN SNCMCDMEYCLVBO-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- INOIOAWTVPHTCJ-UHFFFAOYSA-N 6-acetamido-4-hydroxy-3-[[4-(2-sulfooxyethylsulfonyl)phenyl]diazenyl]naphthalene-2-sulfonic acid Chemical compound CC(=O)NC1=CC=C2C=C(C(N=NC3=CC=C(C=C3)S(=O)(=O)CCOS(O)(=O)=O)=C(O)C2=C1)S(O)(=O)=O INOIOAWTVPHTCJ-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 239000012988 Dithioester Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 150000003926 acrylamides Chemical class 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- JQDCYGOHLMJDNA-UHFFFAOYSA-N bis(oxiran-2-ylmethyl) butanedioate Chemical compound C1OC1COC(=O)CCC(=O)OCC1CO1 JQDCYGOHLMJDNA-UHFFFAOYSA-N 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000005022 dithioester group Chemical group 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000003505 polymerization initiator Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- WXQMFIJLJLLQIS-UHFFFAOYSA-N reactive blue 21 Chemical compound [Cu+2].C1=CC(S(=O)(=O)CCO)=CC=C1NS(=O)(=O)C1=CC=C2C([N-]3)=NC(C=4C5=CC=C(C=4)S(O)(=O)=O)=NC5=NC(C=4C5=CC=C(C=4)S(O)(=O)=O)=NC5=NC([N-]4)=C(C=C(C=C5)S(O)(=O)=O)C5=C4N=C3C2=C1 WXQMFIJLJLLQIS-UHFFFAOYSA-N 0.000 description 2
- 239000000985 reactive dye Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940047670 sodium acrylate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- UGIJCMNGQCUTPI-UHFFFAOYSA-N 2-aminoethyl prop-2-enoate Chemical compound NCCOC(=O)C=C UGIJCMNGQCUTPI-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 1
- KFNGWPXYNSJXOP-UHFFFAOYSA-N 3-(2-methylprop-2-enoyloxy)propane-1-sulfonic acid Chemical compound CC(=C)C(=O)OCCCS(O)(=O)=O KFNGWPXYNSJXOP-UHFFFAOYSA-N 0.000 description 1
- OTKLRHWBZHQJOP-UHFFFAOYSA-N 3-aminopropyl prop-2-enoate Chemical compound NCCCOC(=O)C=C OTKLRHWBZHQJOP-UHFFFAOYSA-N 0.000 description 1
- NYUTUWAFOUJLKI-UHFFFAOYSA-N 3-prop-2-enoyloxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC(=O)C=C NYUTUWAFOUJLKI-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 0 CC(C(OCC(NC*)=O)=O)=C Chemical compound CC(C(OCC(NC*)=O)=O)=C 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WNPXCFLOXIFOCI-UHFFFAOYSA-M cesium;2-methylprop-2-enoate Chemical compound [Cs+].CC(=C)C([O-])=O WNPXCFLOXIFOCI-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XHIRWEVPYCTARV-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide;hydrochloride Chemical compound Cl.CC(=C)C(=O)NCCCN XHIRWEVPYCTARV-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- GVHVXOHQWYZWTC-UHFFFAOYSA-N propyl 2-methylprop-2-enoate;hydrochloride Chemical compound Cl.CCCOC(=O)C(C)=C GVHVXOHQWYZWTC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- HFIYIRIMGZMCPC-YOLJWEMLSA-J remazole black-GR Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=C(\N=N\C=3C=CC(=CC=3)S(=O)(=O)CCOS([O-])(=O)=O)C(O)=C2C(N)=C1\N=N\C1=CC=C(S(=O)(=O)CCOS([O-])(=O)=O)C=C1 HFIYIRIMGZMCPC-YOLJWEMLSA-J 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/10—Esters
- C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
- C08F222/102—Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/52—Amides or imides
- C08F120/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F120/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
- C08K5/0025—Crosslinking or vulcanising agents; including accelerators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/05—Alcohols; Metal alcoholates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/80—Medical packaging
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/36—Amides or imides
- C08F222/38—Amides
- C08F222/385—Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters
- C08J2333/14—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/24—Homopolymers or copolymers of amides or imides
- C08J2333/26—Homopolymers or copolymers of acrylamide or methacrylamide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1334—Nonself-supporting tubular film or bag [e.g., pouch, envelope, packet, etc.]
- Y10T428/1341—Contains vapor or gas barrier, polymer derived from vinyl chloride or vinylidene chloride, or polymer containing a vinyl alcohol unit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/21—Circular sheet or circular blank
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Materials For Medical Uses (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Biological Depolymerization Polymers (AREA)
- Medicinal Preparation (AREA)
Description
、またはその誘導体とすることができる。別の実施の形態では、ペプチド系の架橋剤は、
、またはその誘導体とすることができる。ある実施の形態では、ペプチド系の架橋剤は、二官能性メタクリロイル−Ala−Pro−Gly−Leu−AEE−メタクリレートとすることができる。
式中、G、HおよびJは、それぞれ独立して、CH2、O、S、NHまたは存在せず、
a、bおよびcは、それぞれ独立して、1から20であり、
gは、1から20である。
式中、L、MおよびNは、それぞれ独立して、CH2、O、S、NHまたは存在せず、
d、eおよびfは、それぞれ独立して、1から20であり、
hは、1から20である。
乾燥エーテル1000mL中のHEMA24mL(200mmol)に、アルゴン下で4−10℃において、ピリジン16.8mL(213mmol)を加えた。この溶液に、1−クロロエチルクロロカーボネート21.3mL(200mmol)を、30分以上攪拌しながら滴下して加えた。4−10℃での30分の攪拌後、重い沈殿物(化合物B)を濾過により取り除き、濾液を真空下で油状物へ濃縮して、44g(100%)を得た。
、32分で、次の構造式のカーボネートが最終的に出てきた。
乾燥テトラヒドロフラン(THF)250mL中のトリアミノトリメチロールプロパンエトキシレート13.2gに、ピリジン6.32g(80mmol)を加えて、この溶液をよく攪拌しながらアルゴン下で4−10℃においてTHF250mL中のクロロアセチルクロリド6.44gに加えた。15分間攪拌した後、反応混合物を室温まで温めて、THFおよび他の揮発性物質を真空下で除去した。得られた固体を、クロロホルム200mL中に溶解させて、次に、当該クロロホルムを飽和重炭酸ナトリウム水溶液100mLで洗浄して、硫酸マグネシウムで乾燥させて、溶媒を真空中で除去した。
無水ジメチルホルムアミド75mL中に溶解させた約15gの上記物質に、セシウムメタクリレート18gを加えて、得られた懸濁液を40−50℃で2時間加熱した。
本出願は、2013年9月19日に提出された米国仮特許出願第61/880029号の利益を主張しており、その全体の記載は参照によりここに組み込まれる。
(付記1)
少なくとも1つの官能基を含む少なくとも1つのモノマー、および、
少なくとも1つの架橋剤、を含み、
約40μmと約1200μmとの間の厚さを有しており、生分解性である、
ポリマーフィルム。
前記ポリマーフィルムは、円形、正方形、長方形、三角形、楕円形または五角形から選択される形状を有する、付記1に記載のポリマーフィルム。
前記少なくとも1つの官能基は、アクリレート、アクリルアミド、メタクリレートまたはメタクリルアミドである、付記1に記載のポリマーフィルム。
前記少なくとも1つのモノマーは、イオン化可能な官能基を含む、付記1に記載のポリマーフィルム。
前記イオン化可能な官能基は、塩基性である、付記4に記載のポリマーフィルム。
前記イオン化可能な官能基は、酸性である、付記4に記載のポリマーフィルム。
前記少なくとも1つの架橋剤は、少なくとも2つの官能基を含む、付記1に記載のポリマーフィルム。
前記架橋剤は、加水分解または酵素作用による分解を受け易い少なくとも1つの結合を含む、付記1に記載のポリマーフィルム。
前記架橋剤は、ビス−グリシジルアミノアルコールである、付記8に記載のポリマーフィルム。
前記少なくとも1つの結合は、エステル、チオエステル、カーボネート、カルバメート、マトリクスメタロプロテイナーゼにより切断可能なペプチド、マトリクスコラゲナーゼにより切断可能なペプチド、マトリクスエラスターゼにより切断可能なペプチド、マトリクスカテプシンにより切断可能なペプチド、または、それらの組み合わせである、付記8に記載のポリマーフィルム。
エステル、チオエステル、カーボネート、カルバメート、マトリクスメタロプロテイナーゼにより切断可能なペプチド、マトリクスコラゲナーゼにより切断可能なペプチド、マトリクスエラスターゼにより切断可能なペプチド、および、マトリクスカテプシンにより切断可能なペプチドから選択される第2の結合を含む第2の架橋剤を含む、付記11に記載のポリマーフィルム。
前記ポリマーフィルムは、移植後約6ヶ月以内に、実質的に分解される、付記1に記載のポリマーフィルム。
前記ポリマーフィルムは、移植後約1ヶ月以内に、実質的に分解される、付記1に記載のポリマーフィルム。
前記少なくとも1つのモノマーはアクリルアミドであり、前記少なくとも1つの架橋剤はビス−グリシジルアミノアルコールである、付記1に記載のポリマーフィルム。
前記少なくとも1つのモノマーはアクリルアミドであり、前記少なくとも1つの架橋剤は二官能性メタクリロイル−Ala−Pro−Gly−Leu−AEE−メタクリレートである、付記1に記載のポリマーフィルム。
少なくとも1つの官能基を含む少なくとも1つのモノマーと、分解を受け易い少なくとも1つの架橋剤と、開始剤とを含むプレポリマー溶液を反応させること、および、
約40μmと約1200μmとの間の厚さを有するポリマーフィルムを形成させること、を含む、ポリマーフィルムを製造する方法。
前記フィルムは、少なくとも1つのスペーサーを含む2つのプレートの間に形成される、付記17に記載の方法。
前記開始剤は、N,N,N’,N’−テトラメチルエチレンジアミンである、付記17に記載の方法。
前記ポリマーフィルムは、円形、正方形、長方形、三角形、楕円形または五角形から選択される形状を有する、付記17に記載の方法。
前記少なくとも1つの官能基は、アクリレート、アクリルアミド、メタクリレートまたはメタクリルアミドである、付記17に記載の方法。
前記少なくとも1つの架橋剤は、ビス−グリシジルアミノアルコールである、付記17に記載の方法。
前記ポリマーフィルムは、生分解性である、付記17に記載の方法。
前記ポリマーフィルムは、移植後約1ヶ月以内に、実質的に分解される、付記24に記載の方法。
前記少なくとも1つのモノマーはアクリルアミドであり、前記少なくとも1つの架橋剤はビス−グリシジルアミノアルコールである、付記24に記載の方法。
前記少なくとも1つのモノマーはアクリルアミドであり、前記少なくとも1つの架橋剤は二官能性メタクリロイル−Ala−Pro−Gly−Leu−AEE−メタクリレートである、付記24に記載の方法。
Claims (23)
- 前記ポリマーフィルムは、円形、正方形、長方形、三角形、楕円形または五角形から選択される形状を有する、請求項1に記載のポリマーフィルム。
- 前記少なくとも1つの官能基は、アクリレート、アクリルアミド、メタクリレートまたはメタクリルアミドである、請求項1に記載のポリマーフィルム。
- 前記少なくとも1つのモノマーは、イオン化可能な官能基を含む、請求項1に記載のポリマーフィルム。
- 前記イオン化可能な官能基は、塩基性である、請求項4に記載のポリマーフィルム。
- 前記イオン化可能な官能基は、酸性である、請求項4に記載のポリマーフィルム。
- 前記少なくとも1つの架橋剤は、少なくとも2つの官能基を含む、請求項1に記載のポリマーフィルム。
- 前記架橋剤は、加水分解または酵素作用による分解を受け易い少なくとも1つの結合を含む、請求項1に記載のポリマーフィルム。
- 前記少なくとも1つの結合は、エステル、チオエステル、カーボネート、カルバメート、マトリクスメタロプロテイナーゼにより切断可能なペプチド、マトリクスコラゲナーゼにより切断可能なペプチド、マトリクスエラスターゼにより切断可能なペプチド、マトリクスカテプシンにより切断可能なペプチド、または、それらの組み合わせである、請求項8に記載のポリマーフィルム。
- エステル、チオエステル、カーボネート、カルバメート、マトリクスメタロプロテイナーゼにより切断可能なペプチド、マトリクスコラゲナーゼにより切断可能なペプチド、マトリクスエラスターゼにより切断可能なペプチド、および、マトリクスカテプシンにより切断可能なペプチドから選択される第2の結合を含む第2の架橋剤を含む、請求項9に記載のポリマーフィルム。
- 前記ポリマーフィルムは、移植後約6ヶ月以内に分解される、請求項1に記載のポリマーフィルム。
- 前記ポリマーフィルムは、移植後約1ヶ月以内に分解される、請求項1に記載のポリマーフィルム。
- 前記フィルムは、少なくとも1つのスペーサーを含む2つのプレートの間に形成される、請求項15に記載の方法。
- 前記開始剤は、N,N,N’,N’−テトラメチルエチレンジアミンである、請求項15に記載の方法。
- 前記ポリマーフィルムは、円形、正方形、長方形、三角形、楕円形または五角形から選択される形状を有する、請求項15に記載の方法。
- 前記少なくとも1つの官能基は、アクリレート、アクリルアミド、メタクリレートまたはメタクリルアミドである、請求項15に記載の方法。
- 前記ポリマーフィルムは、生分解性である、請求項15に記載の方法。
- 前記ポリマーフィルムは、移植後約1ヶ月以内に分解される、請求項20に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361880029P | 2013-09-19 | 2013-09-19 | |
US61/880,029 | 2013-09-19 | ||
PCT/US2014/056647 WO2015042462A1 (en) | 2013-09-19 | 2014-09-19 | Polymer films |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019238182A Division JP2020097740A (ja) | 2013-09-19 | 2019-12-27 | ポリマーフィルム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016531955A JP2016531955A (ja) | 2016-10-13 |
JP6641265B2 true JP6641265B2 (ja) | 2020-02-05 |
Family
ID=52668197
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016515393A Active JP6641265B2 (ja) | 2013-09-19 | 2014-09-19 | ポリマーフィルム |
JP2019238182A Pending JP2020097740A (ja) | 2013-09-19 | 2019-12-27 | ポリマーフィルム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019238182A Pending JP2020097740A (ja) | 2013-09-19 | 2019-12-27 | ポリマーフィルム |
Country Status (9)
Country | Link |
---|---|
US (3) | US9408916B2 (ja) |
EP (1) | EP3046956B1 (ja) |
JP (2) | JP6641265B2 (ja) |
KR (2) | KR102505172B1 (ja) |
CN (1) | CN105555847B (ja) |
AU (1) | AU2014321278B2 (ja) |
BR (1) | BR112016005768B1 (ja) |
CA (1) | CA2923741C (ja) |
WO (1) | WO2015042462A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2923741C (en) | 2013-09-19 | 2022-06-07 | Microvention, Inc. | Polymer films |
BR112016005770B1 (pt) | 2013-09-19 | 2021-07-27 | Terumo Corporation | Partículas de polímero |
KR102287781B1 (ko) | 2013-11-08 | 2021-08-06 | 테루모 가부시키가이샤 | 중합체 입자 |
US9265512B2 (en) | 2013-12-23 | 2016-02-23 | Silk Road Medical, Inc. | Transcarotid neurovascular catheter |
EP3253437B1 (en) | 2015-02-04 | 2019-12-04 | Route 92 Medical, Inc. | Rapid aspiration thrombectomy system |
US11065019B1 (en) | 2015-02-04 | 2021-07-20 | Route 92 Medical, Inc. | Aspiration catheter systems and methods of use |
US9907880B2 (en) | 2015-03-26 | 2018-03-06 | Microvention, Inc. | Particles |
WO2017019563A1 (en) | 2015-07-24 | 2017-02-02 | Route 92 Medical, Inc. | Anchoring delivery system and methods |
WO2017147493A1 (en) | 2016-02-24 | 2017-08-31 | Incept, Llc | Enhanced flexibility neurovascular catheter |
CA3038642C (en) | 2016-09-28 | 2021-11-02 | Terumo Corporation | Polymer particles comprising polymerizable pharmaceutical agents |
KR101868113B1 (ko) * | 2016-12-19 | 2018-06-18 | 주식회사 인터코스 | 마스크팩의 제조방법 |
US10653426B2 (en) | 2017-01-06 | 2020-05-19 | Incept, Llc | Thromboresistant coatings for aneurysm treatment devices |
WO2018132387A1 (en) | 2017-01-10 | 2018-07-19 | Route 92 Medical, Inc. | Aspiration catheter systems and methods of use |
CN112203593A (zh) | 2018-05-01 | 2021-01-08 | 因赛普特有限责任公司 | 用于从血管内部位去除闭塞性物质的装置和方法 |
US11395665B2 (en) | 2018-05-01 | 2022-07-26 | Incept, Llc | Devices and methods for removing obstructive material, from an intravascular site |
CN115920204A (zh) | 2018-05-17 | 2023-04-07 | 92号医疗公司 | 抽吸导管系统和使用方法 |
US11471582B2 (en) | 2018-07-06 | 2022-10-18 | Incept, Llc | Vacuum transfer tool for extendable catheter |
US11517335B2 (en) | 2018-07-06 | 2022-12-06 | Incept, Llc | Sealed neurovascular extendable catheter |
US11766539B2 (en) | 2019-03-29 | 2023-09-26 | Incept, Llc | Enhanced flexibility neurovascular catheter |
WO2021076642A1 (en) | 2019-10-15 | 2021-04-22 | Imperative Care, Inc. | Systems and methods for multivariate stroke detection |
EP4076611A4 (en) | 2019-12-18 | 2023-11-15 | Imperative Care, Inc. | METHODS AND SYSTEMS FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC DISEASE |
US20210315598A1 (en) | 2019-12-18 | 2021-10-14 | Imperative Care, Inc. | Methods of placing large bore aspiration catheters |
US11638637B2 (en) | 2019-12-18 | 2023-05-02 | Imperative Care, Inc. | Method of removing embolic material with thrombus engagement tool |
EP4117762A4 (en) | 2020-03-10 | 2024-05-08 | Imperative Care, Inc. | NEUROVASCULAR CATHETER WITH INCREASED FLEXIBILITY |
US11207497B1 (en) | 2020-08-11 | 2021-12-28 | Imperative Care, Inc. | Catheter with enhanced tensile strength |
Family Cites Families (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4070348A (en) | 1973-07-25 | 1978-01-24 | Rohm Gmbh | Water-swellable, bead copolymer |
US4157323A (en) | 1976-06-09 | 1979-06-05 | California Institute Of Technology | Metal containing polymeric functional microspheres |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
FR2596399B1 (fr) | 1986-03-28 | 1988-09-02 | Univ Rennes | Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament |
US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
FR2676927B1 (fr) | 1991-05-29 | 1995-06-23 | Ibf | Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant. |
US5545423A (en) | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
AU673160B2 (en) | 1992-02-28 | 1996-10-31 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
JPH05279416A (ja) * | 1992-03-31 | 1993-10-26 | Ajinomoto Co Inc | 親水性生分解性高分子 |
ES2138070T3 (es) | 1992-12-23 | 2000-01-01 | Saitec Srl | Proceso para la preparacion de formas farmaceuticas de liberacion controlada y las formas obtenidas de esta manera. |
NO940115D0 (no) | 1994-01-13 | 1994-01-13 | Nycomed Imaging As | Kontrastmidler for roentgen- og magnettomografisk avbildning |
US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
GB9406094D0 (en) | 1994-03-28 | 1994-05-18 | Univ Nottingham And University | Polymer microspheres and a method of production thereof |
DE19543366C2 (de) | 1995-11-21 | 1998-09-10 | Stockhausen Chem Fab Gmbh | Mit ungesättigten Aminoalkoholen vernetzte, wasserquellbare Polymerisate, deren Herstellung und Verwendung |
US5906997A (en) | 1997-06-17 | 1999-05-25 | Fzio Med, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
US6048908A (en) | 1997-06-27 | 2000-04-11 | Biopore Corporation | Hydrophilic polymeric material |
SE9704401D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | Matrix pellets for greasy, oily or sticky drug substances |
AU742786B2 (en) | 1998-03-06 | 2002-01-10 | Biosphere Medical, Inc. | Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
FR2784580B1 (fr) | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
US8802146B2 (en) | 1998-11-06 | 2014-08-12 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6521431B1 (en) | 1999-06-22 | 2003-02-18 | Access Pharmaceuticals, Inc. | Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments |
JP2003525682A (ja) | 2000-03-06 | 2003-09-02 | シメッド ライフ システムズ インコーポレイテッド | 超音波下で目視できる塞栓剤 |
ES2253360T3 (es) | 2000-03-13 | 2006-06-01 | Biocure, Inc. | Articulos biomedicos a base de hidrogel. |
US6436424B1 (en) | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
DE01918975T1 (de) | 2000-03-24 | 2006-04-13 | Biosphere Medical, Inc., Rockland | Mikrokügelchen zur aktiven Embolisierung |
US7858119B1 (en) | 2000-05-09 | 2010-12-28 | Amina Odidi | Extended release pharmaceuticals |
EP1305064B1 (en) | 2000-07-28 | 2008-04-23 | Anika Therapeutics Inc. | Bioabsorbable composites of derivatized hyaluronic acid |
JP2004522808A (ja) * | 2000-08-23 | 2004-07-29 | フェアーソン・メディカル・インコーポレーテッド | 新規のポリマー化合物 |
AU2000269264A1 (en) * | 2000-08-23 | 2002-03-04 | Eidgenossische Technische Hochschule Zurich (Eth) | Treatment of trauma, and other indications |
US6878384B2 (en) * | 2001-03-13 | 2005-04-12 | Microvention, Inc. | Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use |
AU2002248792B2 (en) | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
US6685956B2 (en) | 2001-05-16 | 2004-02-03 | The Research Foundation At State University Of New York | Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications |
ATE410459T1 (de) | 2002-01-14 | 2008-10-15 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
WO2003064279A1 (en) | 2002-01-28 | 2003-08-07 | Coloplast A/S | Easy to open package |
JP2003245544A (ja) | 2002-02-21 | 2003-09-02 | Dainippon Ink & Chem Inc | 吸水性材料 |
US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
US7838699B2 (en) | 2002-05-08 | 2010-11-23 | Biosphere Medical | Embolization using degradable crosslinked hydrogels |
JP4120832B2 (ja) | 2002-06-17 | 2008-07-16 | 日本電気株式会社 | 生分解性樹脂、生分解性樹脂組成物、生分解性成形体、生分解性樹脂の製造方法 |
GB2399084B (en) | 2002-07-30 | 2007-01-31 | Univ Liverpool | Porous beads and method of production thereof |
EP1534351B1 (en) | 2002-08-09 | 2006-10-04 | Boston Scientific Limited | Embolization |
US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
EP1559440B1 (en) | 2002-10-29 | 2015-09-23 | Toray Industries, Inc. | Vascular embolization meterial |
CN100418619C (zh) | 2003-01-17 | 2008-09-17 | 康乃尔研究基金会有限公司 | 可注射水凝胶微球和形成水凝胶微球的方法 |
US7144588B2 (en) | 2003-01-17 | 2006-12-05 | Synovis Life Technologies, Inc. | Method of preventing surgical adhesions |
US20040161466A1 (en) | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
CA2518557C (en) | 2003-03-14 | 2012-06-26 | National Institute Of Advanced Industrial Science And Technology | Methods for producing macromolecule identifying polymers |
AU2004263130A1 (en) | 2003-08-06 | 2005-02-17 | Nirmal Mulye | Pharmaceutical composition containing water soluble drug |
US7192693B2 (en) * | 2004-02-24 | 2007-03-20 | University Of Washington | Methods for photopatterning hydrogels |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US20050267556A1 (en) | 2004-05-28 | 2005-12-01 | Allan Shuros | Drug eluting implants to prevent cardiac apoptosis |
EP3085361A1 (en) | 2004-09-07 | 2016-10-26 | Biocompatibles UK Limited | Compositions comprising camptothecins in microspheres |
EP2287205A3 (en) * | 2004-09-15 | 2012-08-01 | Seikagaku Corporation | Photoreactive polysaccharide. photocrosslinked polysaccharide products, the method of making them and medical materials made therefrom |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US7332159B2 (en) | 2004-09-30 | 2008-02-19 | Board Of Regents Of The University Of Nebraska | Method and composition for inhibiting reperfusion injury in the brain |
US9107850B2 (en) | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
BRPI0518383A2 (pt) | 2004-10-25 | 2008-11-18 | Polyzenix Gmbh | partÍculas polimÉricas carregÁveis para aplicaÇÕes terepÊuticas e/ou diagnàstico e mÉtodos para preparar e usar as mesmas |
US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US9114162B2 (en) | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
DE602006016915D1 (de) | 2005-01-28 | 2010-10-28 | Tepha Inc | Embolisierung unter verwendung von poly-4-hydroxybutyrat-partikeln |
US20060222596A1 (en) | 2005-04-01 | 2006-10-05 | Trivascular, Inc. | Non-degradable, low swelling, water soluble radiopaque hydrogel polymer |
KR100618382B1 (ko) | 2005-05-03 | 2006-08-31 | 삼성전자주식회사 | 혈액의 핵자기 공명 종축 이완시간을 측정하는 방법 및장치 |
EP1879554B2 (en) | 2005-05-09 | 2018-03-07 | Biosphere Medical, S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
US8343546B2 (en) | 2005-09-13 | 2013-01-01 | Coating Place, Inc. | Ion exchange resin treated to control swelling |
JP2009508991A (ja) | 2005-09-15 | 2009-03-05 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | ポリマー組成物ならびにその作製方法および使用方法 |
EP1973493A2 (en) * | 2006-01-12 | 2008-10-01 | Massachusetts Institute of Technology | Biodegradable elastomers |
US20080033366A1 (en) | 2006-01-30 | 2008-02-07 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
WO2007090130A2 (en) | 2006-01-30 | 2007-08-09 | Surgica Corporation | Porous intravascular embolization particles and related methods |
WO2007090897A1 (en) | 2006-02-10 | 2007-08-16 | Biocompatibles Uk Limited | Loading of hydrophobic drugs into hydrophilic polymer delivery systems |
JP2009528412A (ja) | 2006-02-28 | 2009-08-06 | エフォニック ストックハウゼン ゲーエムベーハー | 優れた吸収性及び保持性を有する生分解性超吸収性ポリマー組成物 |
US7794755B2 (en) | 2006-04-11 | 2010-09-14 | E.I. Du Pont De Nemours And Company | Process for preparation of swellable and deformable microspheres |
US8062673B2 (en) | 2006-04-11 | 2011-11-22 | E I Du Pont De Nemours And Company | Process for embolization using swellable and deformable microspheres |
US8252339B2 (en) | 2006-04-11 | 2012-08-28 | Massachusetts Institute Of Technology | Medical treatment applications of swellable and deformable microspheres |
US7838035B2 (en) | 2006-04-11 | 2010-11-23 | E. I. Du Pont De Nemours And Company | Microsphere powder of high density, swellable, deformable, durable occlusion-forming microspheres |
KR100722607B1 (ko) | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
EP2019691B1 (en) | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
FR2906253A1 (fr) | 2006-09-22 | 2008-03-28 | Biosphere Medical Sa | Nouveaux materiaux polymeres bio-compatibles, leur procede d'obtention et leurs utilisations, notamment en imagerie medicale par resonnance magnetique |
WO2008057163A2 (en) | 2006-10-09 | 2008-05-15 | Carnegie Mellon University | Preparation of functional gel particles with a dual crosslink network |
GB0620504D0 (en) | 2006-10-16 | 2006-11-22 | Queen Mary & Westfield College | Method |
CA2685965A1 (en) * | 2007-03-30 | 2008-10-09 | Medivas, Llc | Bioabsorbable elastomeric polymer networks, cross-linkers and methods of use |
EP1985286A1 (en) | 2007-04-24 | 2008-10-29 | Biocompatibles UK Limited | Microspheres for treatment of brain tumours |
JP5443976B2 (ja) | 2007-05-01 | 2014-03-19 | 国立大学法人 東京医科歯科大学 | 化学架橋ヒアルロン酸誘導体を含むハイブリッドゲルおよびそれを用いた医薬組成物 |
KR100899147B1 (ko) | 2007-05-04 | 2009-05-27 | 한양대학교 산학협력단 | 메타 데이터 저장 방법 및 메타 데이터 저장 시스템 |
EP2178502A2 (en) | 2007-06-21 | 2010-04-28 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
US8110226B2 (en) | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
WO2009015281A2 (en) | 2007-07-25 | 2009-01-29 | Basf Corporation | Epoxy and hydroxy-functional acrylic resins for use in coating applications |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7887846B2 (en) | 2007-08-07 | 2011-02-15 | E. I. Du Pont De Nemours And Company | Process for preparation of swellable and degradable microspheres |
GB0717516D0 (en) * | 2007-09-07 | 2007-10-17 | Imp Innovations Ltd | Bioactive nanocomposite material |
EP2205224A1 (en) | 2007-09-26 | 2010-07-14 | DSM IP Assets B.V. | Microparticle comprising cross-linked polymer |
US9107828B2 (en) | 2007-10-05 | 2015-08-18 | Boston Scientific Scimed, Inc. | Multi-component particles for injection and processes for forming the same |
US8246998B2 (en) | 2007-11-01 | 2012-08-21 | Boston Scientific Scimed, Inc. | Injectable biodegradable particles |
US20110104052A1 (en) | 2007-12-03 | 2011-05-05 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
CA2709379C (en) | 2007-12-21 | 2016-08-16 | Microvention, Inc. | Hydrogel filaments for biomedical uses |
EP2249960A1 (en) | 2008-03-06 | 2010-11-17 | E. I. du Pont de Nemours and Company | Process for making coated, water-swellable hydrogel microspheres |
US20110009520A1 (en) | 2008-03-20 | 2011-01-13 | Figuly Garret D | Dimensionally stable, shaped articles comprised of dried, aggregated, water-swellable hydrogel microspheres and method of making same |
US8114436B2 (en) | 2008-03-25 | 2012-02-14 | Boston Scientific Scimed, Inc. | Compositions and methods for delivery of embolics |
ES2718477T3 (es) | 2008-03-28 | 2019-07-02 | Biotage Ab | Material compuesto |
GB2471977B (en) | 2008-04-21 | 2012-10-24 | Nalco Co | Composition and method for recovering hydrocarbon fluids from a subterranean reservoir |
US20110158910A1 (en) | 2008-04-25 | 2011-06-30 | Aylvin Jorge Angelo Athanasius Dias | Microparticles comprising polymers with thioester bonds |
US8557288B2 (en) | 2008-08-15 | 2013-10-15 | Washington University | Hydrogel microparticle formation in aqueous solvent for biomedical applications |
KR101597829B1 (ko) | 2008-08-20 | 2016-02-26 | 코오롱인더스트리 주식회사 | 다공성 막 및 그 제조방법 |
WO2010062678A2 (en) | 2008-10-30 | 2010-06-03 | David Liu | Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same |
WO2010063630A2 (en) | 2008-12-02 | 2010-06-10 | Biocompatibles Uk Limited | Pancreatic tumour treatment |
JP5597204B2 (ja) * | 2008-12-16 | 2014-10-01 | カールスベア アー/エス | 気相グラフティングによってヒドロキシル化された表面のコーティング |
JP2012100680A (ja) | 2009-03-04 | 2012-05-31 | Terumo Corp | 血管内用処置材 |
JP2010227172A (ja) | 2009-03-26 | 2010-10-14 | Terumo Corp | 軟組織増大材料 |
US8481067B2 (en) | 2009-06-04 | 2013-07-09 | Clemson University Research Foundation | Methods for promoting the revascularization and reenervation of CNS lesions |
WO2011014722A2 (en) | 2009-07-30 | 2011-02-03 | Cook Incorporated | Erodible embolization material |
US20110033548A1 (en) | 2009-08-05 | 2011-02-10 | E.I. Du Pont De Nemours And Company | Degradable crosslinked aminated dextran microspheres and methods of use |
US20110038936A1 (en) | 2009-08-17 | 2011-02-17 | Kimberly Ann Griswold | System and method for electrospun drug loaded biodegradable chemotherapy applications |
EP2295480A1 (en) | 2009-09-10 | 2011-03-16 | Occlugel | Implantable bio-resorbable polymer |
EP2803370B1 (en) | 2009-10-06 | 2019-02-27 | Regents of the University of Minnesota | Bioresorbable embolization microspheres |
RU2012125200A (ru) | 2009-12-04 | 2014-01-20 | Магле Аб | Микросферы гидролизованного крахмала с эндогенными заряженными лигандами |
US8366661B2 (en) | 2009-12-18 | 2013-02-05 | Boston Scientific Scimed, Inc. | Medical device with expandable body for drug delivery by capsules |
EP2351779B1 (en) | 2010-01-27 | 2019-04-24 | Biosphere Medical, Inc. | Microspheres and method of making the microspheres |
CN102834104A (zh) | 2010-02-22 | 2012-12-19 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
JP2011201031A (ja) | 2010-03-24 | 2011-10-13 | Dic Corp | 積層構造を有する高分子基材、及びそれを用いた医療器具 |
JP2011245267A (ja) | 2010-04-27 | 2011-12-08 | Dic Corp | 硫酸化多糖固定化多孔性高分子基材及び医療器具 |
US8772355B2 (en) | 2010-11-23 | 2014-07-08 | Howard University | Stealth polymeric particles for delivery of bioactive or diagnostic agents |
JP6038801B2 (ja) | 2010-11-29 | 2016-12-07 | セントレ ホスピタリエ ユニヴェルシテール ヴォードワ | 抗血管新生薬を含む化学塞栓療法組成物 |
JP2012170773A (ja) | 2011-02-24 | 2012-09-10 | Hamamatsu Univ School Of Medicine | 制御ラジカル重合反応を利用して得られる糖類固定化高分子基材、及び医療器具 |
JP5140211B2 (ja) | 2011-03-04 | 2013-02-06 | Dic株式会社 | 糖類固定化ウイルス除去用基材、及びウイルスの除去器具 |
EP2683750B1 (en) | 2011-03-09 | 2017-04-19 | Occlugel | Implantable swellable bio-resorbable polymer |
JP2012187308A (ja) | 2011-03-11 | 2012-10-04 | Hamamatsu Univ School Of Medicine | 硫酸化多糖固定化基材、及びそれを用いたウイルスの除去方法 |
WO2012133737A1 (ja) * | 2011-03-31 | 2012-10-04 | 公益財団法人地球環境産業技術研究機構 | 架橋性アミン化合物、該化合物を用いた高分子膜及びその製造方法 |
US9456823B2 (en) | 2011-04-18 | 2016-10-04 | Terumo Corporation | Embolic devices |
CN103796683A (zh) * | 2011-04-21 | 2014-05-14 | 塔夫茨大学信托人 | 用于活性试剂稳定化的方法和组合物 |
EP2714721A4 (en) * | 2011-05-27 | 2014-11-19 | Univ Akron | BIOACTIVE POLYMERIC MATERIALS CROSS-LINKED BY A PEPTIDE |
WO2013130143A2 (en) | 2011-12-01 | 2013-09-06 | The Regents Of The University Of California | Polaniline based membranes for separation of carbon dioxide and methane |
ES2655656T3 (es) | 2012-05-24 | 2018-02-21 | Biosphere Medical Inc. | Biomateriales adecuados para usar como implantes detectables mediante imagen de resonancia magnética, eluyentes de fármacos para oclusión vascular |
JP2015512422A (ja) | 2012-05-30 | 2015-04-27 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 治療剤制御放出用の注射可能な生分解性粒子 |
WO2014034787A1 (ja) | 2012-08-31 | 2014-03-06 | Dic株式会社 | ウイルス除去可能な透析装置 |
TWI519339B (zh) | 2012-12-28 | 2016-02-01 | 財團法人工業技術研究院 | 過濾膜 |
JP6031405B2 (ja) | 2013-05-01 | 2016-11-24 | 株式会社Adeka | ベンゾトリアゾール化合物 |
BR112016005770B1 (pt) | 2013-09-19 | 2021-07-27 | Terumo Corporation | Partículas de polímero |
CA2923741C (en) | 2013-09-19 | 2022-06-07 | Microvention, Inc. | Polymer films |
KR102287781B1 (ko) | 2013-11-08 | 2021-08-06 | 테루모 가부시키가이샤 | 중합체 입자 |
CN103709323A (zh) | 2013-12-04 | 2014-04-09 | 天津工业大学 | 一种肝靶向温敏微球及其制备方法 |
CN110433326A (zh) | 2014-04-29 | 2019-11-12 | 微仙美国有限公司 | 包含活性剂的聚合物 |
US9907880B2 (en) | 2015-03-26 | 2018-03-06 | Microvention, Inc. | Particles |
CA3038642C (en) | 2016-09-28 | 2021-11-02 | Terumo Corporation | Polymer particles comprising polymerizable pharmaceutical agents |
-
2014
- 2014-09-19 CA CA2923741A patent/CA2923741C/en active Active
- 2014-09-19 KR KR1020217040855A patent/KR102505172B1/ko active IP Right Grant
- 2014-09-19 WO PCT/US2014/056647 patent/WO2015042462A1/en active Application Filing
- 2014-09-19 BR BR112016005768-6A patent/BR112016005768B1/pt active IP Right Grant
- 2014-09-19 KR KR1020167007854A patent/KR102340388B1/ko active IP Right Grant
- 2014-09-19 CN CN201480051681.2A patent/CN105555847B/zh active Active
- 2014-09-19 EP EP14845609.8A patent/EP3046956B1/en active Active
- 2014-09-19 US US14/491,813 patent/US9408916B2/en active Active
- 2014-09-19 JP JP2016515393A patent/JP6641265B2/ja active Active
- 2014-09-19 AU AU2014321278A patent/AU2014321278B2/en active Active
-
2016
- 2016-06-30 US US15/199,633 patent/US10227463B2/en active Active
-
2019
- 2019-01-25 US US16/258,313 patent/US11104772B2/en active Active
- 2019-12-27 JP JP2019238182A patent/JP2020097740A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190194406A1 (en) | 2019-06-27 |
EP3046956B1 (en) | 2019-08-28 |
KR20210156300A (ko) | 2021-12-24 |
CA2923741A1 (en) | 2015-03-26 |
BR112016005768A2 (pt) | 2017-11-21 |
US11104772B2 (en) | 2021-08-31 |
US20150079328A1 (en) | 2015-03-19 |
KR20160060051A (ko) | 2016-05-27 |
WO2015042462A1 (en) | 2015-03-26 |
KR102505172B1 (ko) | 2023-02-28 |
CA2923741C (en) | 2022-06-07 |
KR102340388B1 (ko) | 2021-12-17 |
US20160311990A1 (en) | 2016-10-27 |
JP2016531955A (ja) | 2016-10-13 |
JP2020097740A (ja) | 2020-06-25 |
EP3046956A4 (en) | 2017-05-17 |
CN105555847B (zh) | 2018-08-10 |
BR112016005768B1 (pt) | 2021-09-21 |
EP3046956A1 (en) | 2016-07-27 |
US10227463B2 (en) | 2019-03-12 |
AU2014321278A1 (en) | 2016-03-17 |
CN105555847A (zh) | 2016-05-04 |
US9408916B2 (en) | 2016-08-09 |
AU2014321278B2 (en) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6641265B2 (ja) | ポリマーフィルム | |
JP6648224B2 (ja) | 塞栓システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170629 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6641265 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |